HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

spiruchostatin A

a potent histone deacetylase inhibitor; structure in first source

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - spiruchostatin A: 5
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - spiruchostatin A: 5

Experts

1.	Packham, Graham: 3 articles (05/2012 - 01/2005)
2.	Ganesan, A: 2 articles (08/2008 - 01/2005)
3.	Yurek-George, Alexander: 2 articles (08/2008 - 01/2005)
4.	Aono, Yuichi: 1 article (02/2018)
5.	Horinaka, Mano: 1 article (02/2018)
6.	Miki, Tsuneharu: 1 article (02/2018)
7.	Sakai, Toshiyuki: 1 article (02/2018)
8.	Sowa, Yoshihiro: 1 article (02/2018)
9.	Takamura, Toshiya: 1 article (02/2018)
10.	Toriyama, Seijiro: 1 article (02/2018)

Related Diseases

1.	Neoplasms (Cancer) 08/15/2008 - "Our results demonstrate that spiruchostatin A is a potent inhibitor of class I HDACs and anti-cancer agent. " 08/15/2008 - "Spiruchostatin A was a potent (low nM) inhibitor of the growth of various cancer cell lines. " 08/15/2008 - "We recently completed the total synthesis of spiruchostatin A, a depsipeptide natural product with close structural similarities to FK228, a histone deacetylase (HDAC) inhibitor (HDI) currently being evaluated in clinical trials for cancer. "
2.	Pulmonary Fibrosis (Fibrosing Alveolitis) 05/01/2012 - "Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis."
3.	Lymphoma (Lymphomas) 09/25/2014 - "Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells."
4.	Leukemia 09/25/2014 - "Spiruchostatin A (SP-A) and spiruchostatin B (SP-B) are the potent histone deacetylase inhibitors (HDACi), that has the potential for chemotherapy of leukemia but the exact mechanism of these compounds remains unclear. "
5.	Hypertrophy 01/01/2005 - "We have recently synthesized spiruchostatin A and now show that, although HDACs act in opposition to HATs, spiruchostatin A has the same effect as anacardic acid, that is, it prevents the induction of hypertrophy in response to phenylephrine or urocortin. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Histone Deacetylases (Histone Deacetylase)
3.	Depsipeptides
4.	romidepsin (FK228)
5.	Urocortins
6.	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
7.	Reactive Oxygen Species (Oxygen Radicals)
8.	Phenylephrine (Neo-Synephrine)
9.	infigratinib
10.	spiruchostatin B

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)